Gustav Ullenhag

Optimizing the clinical assessment of pseudoprogression in patients with solid tumors treated with checkpoint inhibitors: a systematic literature review and meta-analysis of associated features

Fountoukidis, Georgios; Tina, Elisabet; Gothlin-Eremo, Anna; Ullenhag, Gustav et al.

Ingår i Cancer Immunology and Immunotherapy, 2026

• DOI för Optimizing the clinical assessment of pseudoprogression in patients with solid tumors treated with checkpoint inhibitors: a systematic literature review and meta-analysis of associated features
• Ladda ner fulltext (pdf) av Optimizing the clinical assessment of pseudoprogression in patients with solid tumors treated with checkpoint inhibitors: a systematic literature review and meta-analysis of associated features

Time of day of neoadjuvant immune checkpoint inhibitor administration is associated with survival but not pathological response in resectable stage III-IV melanoma: A retrospective cohort study

Nelson, Axel; Alghaib, Safa; Björkström, Karl; Isaksson, Karolin et al.

Ingår i European Journal of Cancer, 2026

• DOI för Time of day of neoadjuvant immune checkpoint inhibitor administration is associated with survival but not pathological response in resectable stage III-IV melanoma: A retrospective cohort study
• Ladda ner fulltext (pdf) av Time of day of neoadjuvant immune checkpoint inhibitor administration is associated with survival but not pathological response in resectable stage III-IV melanoma: A retrospective cohort study

Characteristics and overall survival in patients with T1 melanoma: A nationwide matched cohort study

Naeser, Ylva; Mikiver, Rasmus; Isaksson, Karolin; Lambe, Mats et al.

Ingår i International Journal of Cancer, s. 2581-2591, 2026

• DOI för Characteristics and overall survival in patients with T1 melanoma: A nationwide matched cohort study
• Ladda ner fulltext (pdf) av Characteristics and overall survival in patients with T1 melanoma: A nationwide matched cohort study

LOAd703-induced tumor microenvironment gene engineering in combination with atezolizumab in metastatic malignant melanoma: a phase I/II trial

Hamid, O.; Ekström-Rydén, Viktoria; Mehmi, I.; Wang, D. et al.

Ingår i Nature Communications, 2026

• DOI för LOAd703-induced tumor microenvironment gene engineering in combination with atezolizumab in metastatic malignant melanoma: a phase I/II trial
• Ladda ner fulltext (pdf) av LOAd703-induced tumor microenvironment gene engineering in combination with atezolizumab in metastatic malignant melanoma: a phase I/II trial

First-in-human study of intravenous bispecific CTLA-4 × OX40 antibody (ATOR-1015) in advanced solid malignancies

Rydén, Viktoria; Carneiro, A.; Yachnin, J.; Rohrberg, K. Staal et al.

Ingår i ESMO Open, 2026

• DOI för First-in-human study of intravenous bispecific CTLA-4 × OX40 antibody (ATOR-1015) in advanced solid malignancies
• Ladda ner fulltext (pdf) av First-in-human study of intravenous bispecific CTLA-4 × OX40 antibody (ATOR-1015) in advanced solid malignancies

Time of day of neoadjuvant immune checkpoint inhibitor administration is associated with survival but not pathological response in resectable stage III-IV melanoma: A retrospective cohort study

Nelson, Axel; Alghaib, Safa; Björkström, Karl; Isaksson, Karolin et al.

Ingår i European Journal of Cancer, 2026

• DOI för Time of day of neoadjuvant immune checkpoint inhibitor administration is associated with survival but not pathological response in resectable stage III-IV melanoma: A retrospective cohort study
• Ladda ner fulltext (pdf) av Time of day of neoadjuvant immune checkpoint inhibitor administration is associated with survival but not pathological response in resectable stage III-IV melanoma: A retrospective cohort study

Characteristics and overall survival in patients with T1 melanoma: A nationwide matched cohort study

Naeser, Ylva; Mikiver, Rasmus; Isaksson, Karolin; Lambe, Mats et al.

Ingår i International Journal of Cancer, s. 2581-2591, 2026

• DOI för Characteristics and overall survival in patients with T1 melanoma: A nationwide matched cohort study
• Ladda ner fulltext (pdf) av Characteristics and overall survival in patients with T1 melanoma: A nationwide matched cohort study

LOAd703-induced tumor microenvironment gene engineering in combination with atezolizumab in metastatic malignant melanoma: a phase I/II trial

Hamid, O.; Ekström-Rydén, Viktoria; Mehmi, I.; Wang, D. et al.

Ingår i Nature Communications, 2026

• DOI för LOAd703-induced tumor microenvironment gene engineering in combination with atezolizumab in metastatic malignant melanoma: a phase I/II trial
• Ladda ner fulltext (pdf) av LOAd703-induced tumor microenvironment gene engineering in combination with atezolizumab in metastatic malignant melanoma: a phase I/II trial

First-in-human study of intravenous bispecific CTLA-4 × OX40 antibody (ATOR-1015) in advanced solid malignancies

Rydén, Viktoria; Carneiro, A.; Yachnin, J.; Rohrberg, K. Staal et al.

Ingår i ESMO Open, 2026

• DOI för First-in-human study of intravenous bispecific CTLA-4 × OX40 antibody (ATOR-1015) in advanced solid malignancies
• Ladda ner fulltext (pdf) av First-in-human study of intravenous bispecific CTLA-4 × OX40 antibody (ATOR-1015) in advanced solid malignancies

Grand SLAM study protocol: a prospective randomised multicentre study of shortened versus standard duration adjuvant immune checkpoint inhibition for stage IIB-C, III and IV cutaneous melanoma

Ejder, Patric; Jespersen, Henrik; Hernberg, Micaela; Ny, Lars et al.

Ingår i BMC Cancer, 2026

• DOI för Grand SLAM study protocol: a prospective randomised multicentre study of shortened versus standard duration adjuvant immune checkpoint inhibition for stage IIB-C, III and IV cutaneous melanoma
• Ladda ner fulltext (pdf) av Grand SLAM study protocol: a prospective randomised multicentre study of shortened versus standard duration adjuvant immune checkpoint inhibition for stage IIB-C, III and IV cutaneous melanoma

Reprogramming myeloid cells and restoring T cell fitness in checkpoint inhibitor resistant melanoma patients

Grauers Wiktorin, Hanna; Rydén, Viktoria; Ek, Ida; Eriksson, Emma et al.

Ingår i Biomarker Research, 2026

• DOI för Reprogramming myeloid cells and restoring T cell fitness in checkpoint inhibitor resistant melanoma patients
• Ladda ner fulltext (pdf) av Reprogramming myeloid cells and restoring T cell fitness in checkpoint inhibitor resistant melanoma patients

Five-year survival after introduction of adjuvant treatment in stage III melanoma: A nationwide registry-based study

Helgadottir, Hildur; Ny, Lars; Ullenhag, Gustav; Mikiver, Rasmus et al.

Ingår i European Journal of Cancer, 2026

• DOI för Five-year survival after introduction of adjuvant treatment in stage III melanoma: A nationwide registry-based study
• Ladda ner fulltext (pdf) av Five-year survival after introduction of adjuvant treatment in stage III melanoma: A nationwide registry-based study

Physical examinations and whole-body imaging versus physical examinations alone during follow-up after radical surgery of stage IIB-C and III cutaneous malignant melanoma (TRIM): an interim analysis of a multicentre, randomised, phase 3 trial in Sweden

O. Ladjevardi, Cecilia; Naeser, Ylva; Dyrke, Ulf; Papantoniou, Dimitrios et al.

Ingår i The Lancet Oncology, s. 1501-1510, 2025

• DOI för Physical examinations and whole-body imaging versus physical examinations alone during follow-up after radical surgery of stage IIB-C and III cutaneous malignant melanoma (TRIM): an interim analysis of a multicentre, randomised, phase 3 trial in Sweden

Differences in immune-related toxicity between PD-1 and PD-L1 inhibitors: a retrospective cohort study in patients with advanced cancer

Ladjevardi, Cecilia Olsson; Skribek, Marcus; Koliadi, Anthoula; Rydén, Viktoria et al.

Ingår i Cancer Immunology and Immunotherapy, 2025

• DOI för Differences in immune-related toxicity between PD-1 and PD-L1 inhibitors: a retrospective cohort study in patients with advanced cancer
• Ladda ner fulltext (pdf) av Differences in immune-related toxicity between PD-1 and PD-L1 inhibitors: a retrospective cohort study in patients with advanced cancer

Preclinical development and clinical safety assessment of a synthetic peptide conjugate enabling endogenous antibody binding to promote innate receptor engagement

Fletcher, Erika A. K.; Cordfunke, Robert A.; Nasi, Aikaterini; Törnqvist, Gunilla et al.

Ingår i Molecular Therapy Oncology, 2025

• DOI för Preclinical development and clinical safety assessment of a synthetic peptide conjugate enabling endogenous antibody binding to promote innate receptor engagement
• Ladda ner fulltext (pdf) av Preclinical development and clinical safety assessment of a synthetic peptide conjugate enabling endogenous antibody binding to promote innate receptor engagement

Baseline laboratory values and metastatic burden predict survival in addition to IMDC risk in real-world renal cell carcinoma patients treated with ipilimumab-nivolumab

Kheir, Alaa; Johannsdottir, Berglind; Gronn-Weiss, Alexandra; Liu, Lisa L. et al.

Ingår i Acta Oncologica, s. 1355-1364, 2025

• DOI för Baseline laboratory values and metastatic burden predict survival in addition to IMDC risk in real-world renal cell carcinoma patients treated with ipilimumab-nivolumab
• Ladda ner fulltext (pdf) av Baseline laboratory values and metastatic burden predict survival in addition to IMDC risk in real-world renal cell carcinoma patients treated with ipilimumab-nivolumab

Neoadjuvant immunotherapy for patients with resectable stage III/IV cutaneous melanoma: A Swedish retrospective real-world study (NEO-MEL)

Nelson, Axel; Krabbe, Ellen; Björkström, Karl; Huibers, Anne et al.

Ingår i European Journal of Cancer, 2025

• DOI för Neoadjuvant immunotherapy for patients with resectable stage III/IV cutaneous melanoma: A Swedish retrospective real-world study (NEO-MEL)
• Ladda ner fulltext (pdf) av Neoadjuvant immunotherapy for patients with resectable stage III/IV cutaneous melanoma: A Swedish retrospective real-world study (NEO-MEL)

Survival and Quality of Life After Isolated Hepatic Perfusion With Melphalan as a Treatment for Uveal Melanoma Liver Metastases: Final Results From the Phase III Randomized Controlled Trial SCANDIUM

Olofsson Bagge, Roger; Nelson, Axel; Shafazand, Amir; All-Eriksson, Charlotta et al.

Ingår i Annals of Surgery, s. 100-107, 2025

• DOI för Survival and Quality of Life After Isolated Hepatic Perfusion With Melphalan as a Treatment for Uveal Melanoma Liver Metastases: Final Results From the Phase III Randomized Controlled Trial SCANDIUM
• Ladda ner fulltext (pdf) av Survival and Quality of Life After Isolated Hepatic Perfusion With Melphalan as a Treatment for Uveal Melanoma Liver Metastases: Final Results From the Phase III Randomized Controlled Trial SCANDIUM

First-in-human, multicenter, open-label, phase I study of ATOR-1017 (evunzekibart), a 4-1BB antibody, in patients with advanced solid malignancies

Carneiro, Ana; Hahn, Amanda; Ellmark, Peter; Enell Smith, Karin et al.

Ingår i Journal for ImmunoTherapy of Cancer, 2025

• DOI för First-in-human, multicenter, open-label, phase I study of ATOR-1017 (evunzekibart), a 4-1BB antibody, in patients with advanced solid malignancies
• Ladda ner fulltext (pdf) av First-in-human, multicenter, open-label, phase I study of ATOR-1017 (evunzekibart), a 4-1BB antibody, in patients with advanced solid malignancies

Multiple immune-related adverse events secondary to checkpoint inhibitor therapy in patients with advanced cancer: association with treatment effectiveness

Ladjevardi, Cecilia Olsson; Koliadi, Anthoula; Rydén, Viktoria; El-Naggar, Ali Inan et al.

Ingår i Frontiers in Oncology, 2024

• DOI för Multiple immune-related adverse events secondary to checkpoint inhibitor therapy in patients with advanced cancer: association with treatment effectiveness
• Ladda ner fulltext (pdf) av Multiple immune-related adverse events secondary to checkpoint inhibitor therapy in patients with advanced cancer: association with treatment effectiveness

CD40 stimulation via CD40 ligand enhances adenovirus-mediated tumour immunogenicity including 'find-me', 'eat-me', and 'kill-me' signalling

Naseri, Sedigheh; Mejia Cordova, Mariela; Wenthe, Jessica; Lövgren, Tanja et al.

Ingår i Journal of Cellular and Molecular Medicine, 2024

• DOI för CD40 stimulation via CD40 ligand enhances adenovirus-mediated tumour immunogenicity including 'find-me', 'eat-me', and 'kill-me' signalling
• Ladda ner fulltext (pdf) av CD40 stimulation via CD40 ligand enhances adenovirus-mediated tumour immunogenicity including 'find-me', 'eat-me', and 'kill-me' signalling

A phase Ib randomized multicenter trial of isolated hepatic perfusion in combination with ipilimumab and nivolumab for uveal melanoma metastases (SCANDIUM II trial)

Bagge, R. Olofsson; Nelson, A.; Shafazand, A.; Cahlin, C. et al.

Ingår i ESMO Open, 2024

• DOI för A phase Ib randomized multicenter trial of isolated hepatic perfusion in combination with ipilimumab and nivolumab for uveal melanoma metastases (SCANDIUM II trial)
• Ladda ner fulltext (pdf) av A phase Ib randomized multicenter trial of isolated hepatic perfusion in combination with ipilimumab and nivolumab for uveal melanoma metastases (SCANDIUM II trial)

Risk factors for the increasing incidence of pregnancy-associated cancer in Sweden: a population-based study

Lundberg, Frida E.; Stensheim, Hanne; Ullenhag, Gustav; Sahlgren, Hanna Milerad et al.

Ingår i Acta Obstetricia et Gynecologica Scandinavica, s. 669-683, 2024

• DOI för Risk factors for the increasing incidence of pregnancy-associated cancer in Sweden: a population-based study
• Ladda ner fulltext (pdf) av Risk factors for the increasing incidence of pregnancy-associated cancer in Sweden: a population-based study

The role of dacarbazine and temozolomide therapy after treatment with immune checkpoint inhibitors in malignant melanoma patients: A case series and meta-analysis

Rydén, Viktoria; El-Naggar, Ali Inan; Koliadi, Anthoula; Ladjevardi, Cecilia Olsson et al.

Ingår i Pigment Cell & Melanoma Research, 2024

• DOI för The role of dacarbazine and temozolomide therapy after treatment with immune checkpoint inhibitors in malignant melanoma patients: A case series and meta-analysis
• Ladda ner fulltext (pdf) av The role of dacarbazine and temozolomide therapy after treatment with immune checkpoint inhibitors in malignant melanoma patients: A case series and meta-analysis

LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001) results from arm 1 of a non-randomised, single-centre, phase 1/2 study

Musher, Benjamin L.; Rowinsky, Eric K.; Smaglo, Brandon G.; Abidi, Wasif et al.

Ingår i The Lancet Oncology, s. 488-500, 2024

• DOI för LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001) results from arm 1 of a non-randomised, single-centre, phase 1/2 study

Predicting immune-related adverse events using a simplified frailty score in cancer patients treated with checkpoint inhibitors: A retrospective cohort study

Ladjevardi, Cecilia Olsson; Koliadi, Anthoula; Rydén, Viktoria; Inan El-Naggar, Ali et al.

Ingår i Cancer Medicine, s. 13217-13224, 2023

• DOI för Predicting immune-related adverse events using a simplified frailty score in cancer patients treated with checkpoint inhibitors: A retrospective cohort study
• Ladda ner fulltext (pdf) av Predicting immune-related adverse events using a simplified frailty score in cancer patients treated with checkpoint inhibitors: A retrospective cohort study

Survival in patients diagnosed with melanoma in situ compared to the general population. A Swedish population-based matched cohort study

Naeser, Ylva; Mikiver, Rasmus; Ingvar, Christian; Lambe, Mats et al.

Ingår i eClinicalMedicine, 2023

• DOI för Survival in patients diagnosed with melanoma in situ compared to the general population. A Swedish population-based matched cohort study
• Ladda ner fulltext (pdf) av Survival in patients diagnosed with melanoma in situ compared to the general population. A Swedish population-based matched cohort study

Immunostimulatory gene therapy targeting CD40, 4-1BB and IL-2R activates DCs and stimulates antigen-specific T-cell and NK-cell responses in melanoma models

Wenthe, Jessica; Eriksson, Emma; Hellström, Ann-Charlotte; Moreno, Rafael et al.

Ingår i Journal of Translational Medicine, 2023

• DOI för Immunostimulatory gene therapy targeting CD40, 4-1BB and IL-2R activates DCs and stimulates antigen-specific T-cell and NK-cell responses in melanoma models
• Ladda ner fulltext (pdf) av Immunostimulatory gene therapy targeting CD40, 4-1BB and IL-2R activates DCs and stimulates antigen-specific T-cell and NK-cell responses in melanoma models

Survival after introduction of adjuvant treatment in stage III melanoma: a nationwide registry-based study

Helgadottir, Hildur; Ny, Lars; Ullenhag, Gustav; Falkenius, Johan et al.

Ingår i Journal of the National Cancer Institute, s. 1077-1084, 2023

• DOI för Survival after introduction of adjuvant treatment in stage III melanoma: a nationwide registry-based study
• Ladda ner fulltext (pdf) av Survival after introduction of adjuvant treatment in stage III melanoma: a nationwide registry-based study

Chemokine Analysis in Patients with Metastatic Uveal Melanoma Suggests a Role for CCL21 Signaling in Combined Epigenetic Therapy and Checkpoint Immunotherapy

Sah, Vasu R.; Jespersen, Henrik; Karlsson, Joakim; Nilsson, Lisa M. et al.

Ingår i Cancer Research Communications, s. 884-895, 2023

• DOI för Chemokine Analysis in Patients with Metastatic Uveal Melanoma Suggests a Role for CCL21 Signaling in Combined Epigenetic Therapy and Checkpoint Immunotherapy
• Ladda ner fulltext (pdf) av Chemokine Analysis in Patients with Metastatic Uveal Melanoma Suggests a Role for CCL21 Signaling in Combined Epigenetic Therapy and Checkpoint Immunotherapy

Isolated Hepatic Perfusion With Melphalan for Patients With Isolated Uveal Melanoma Liver Metastases: A Multicenter, Randomized, Open-Label, Phase III Trial (the SCANDIUM Trial)

Olofsson Bagge, Roger; Nelson, Axel; Shafazand, Amir; All-Eriksson, Charlotta et al.

Ingår i Journal of Clinical Oncology, s. 3042-3050, 2023

• DOI för Isolated Hepatic Perfusion With Melphalan for Patients With Isolated Uveal Melanoma Liver Metastases: A Multicenter, Randomized, Open-Label, Phase III Trial (the SCANDIUM Trial)

Quality of Life in the First Year of Follow-Up in a Randomized Multicenter Trial Assessing the Role of Imaging after Radical Surgery of Stage IIB-C and III Cutaneous Melanoma (TRIM Study)

Naeser, Ylva; Helgadottir, Hildur; Hansson, Johan; Ingvar, Christian et al.

Ingår i Cancers, 2022

• DOI för Quality of Life in the First Year of Follow-Up in a Randomized Multicenter Trial Assessing the Role of Imaging after Radical Surgery of Stage IIB-C and III Cutaneous Melanoma (TRIM Study)
• Ladda ner fulltext (pdf) av Quality of Life in the First Year of Follow-Up in a Randomized Multicenter Trial Assessing the Role of Imaging after Radical Surgery of Stage IIB-C and III Cutaneous Melanoma (TRIM Study)

Immune priming using DC- and T cell-targeting gene therapy sensitizes both treated and distant B16 tumors to checkpoint inhibition

Wenthe, Jessica; Naseri, Sedigheh; Hellström, Ann-Charlotte; Moreno, Rafael et al.

Ingår i MOLECULAR THERAPY-ONCOLYTICS, s. 429-442, 2022

• DOI för Immune priming using DC- and T cell-targeting gene therapy sensitizes both treated and distant B16 tumors to checkpoint inhibition
• Ladda ner fulltext (pdf) av Immune priming using DC- and T cell-targeting gene therapy sensitizes both treated and distant B16 tumors to checkpoint inhibition

Precision radiation of immune checkpoint therapy resistant melanoma metastases (PROMMEL study): study protocol for a phase II open-label multicenter trial

Backlund, Ellen; Yang, Muyi; Grozman, Vitali; Masucci, Giuseppe et al.

Ingår i Acta Oncologica, s. 869-873, 2022

• DOI för Precision radiation of immune checkpoint therapy resistant melanoma metastases (PROMMEL study): study protocol for a phase II open-label multicenter trial

Evaluation of NTRK immunohistochemistry as a screening method for NTRK gene fusion detection in non-small cell lung cancer

Elfving, Hedvig; Broström, Erika; Moens, Lotte N.J.; Almlöf, Jonas et al.

Ingår i Lung Cancer, s. 53-59, 2021

• DOI för Evaluation of NTRK immunohistochemistry as a screening method for NTRK gene fusion detection in non-small cell lung cancer

A case report of a patient with metastatic uveal melanoma who experienced a complete response to treatment with the NIVO3+IPI1 regimen

Schiza, Aglaia; Naeser, Ylva; Sundin, Anders; Ullenhag, Gustav

Ingår i Clinical Oncology: Case Reports, 2021

Socioeconomy as a prognostic factor for location of death in Swedish palliative cancer patients

Nilsson, Jonas; Holgersson, Georg; Ullenhag, Gustav; Holmgren, Malin et al.

Ingår i BMC Palliative Care, 2021

• DOI för Socioeconomy as a prognostic factor for location of death in Swedish palliative cancer patients
• Ladda ner fulltext (pdf) av Socioeconomy as a prognostic factor for location of death in Swedish palliative cancer patients

Surgery of metastatic melanoma after systemic therapy - the SUMMIST trial: study protocol for a randomized controlled trial

Holmberg, Carl Jacob; Katsarelias, Dimitrios; Jespersen, Henrik; Carneiro, Ana et al.

Ingår i Acta Oncologica, s. 52-55, 2021

• DOI för Surgery of metastatic melanoma after systemic therapy - the SUMMIST trial: study protocol for a randomized controlled trial

Improved survival without increased toxicity with influenza vaccination in cancer patients treated with checkpoint inhibitors

Valachis, Antonios; Rosén, Camilla; Koliadi, Anthoula; Digkas, Evangelos et al.

Ingår i Oncoimmunology, 2021

• DOI för Improved survival without increased toxicity with influenza vaccination in cancer patients treated with checkpoint inhibitors
• Ladda ner fulltext (pdf) av Improved survival without increased toxicity with influenza vaccination in cancer patients treated with checkpoint inhibitors

Cancer survival in women diagnosed with pregnancy-associated cancer: An overview using nationwide registry data in Sweden 1970-2018

Johansson, Anna L.; Fredriksson, Irma; Mellemkjaer, Lene; Stensheim, Hanne et al.

Ingår i European Journal of Cancer, s. 106-115, 2021

• DOI för Cancer survival in women diagnosed with pregnancy-associated cancer: An overview using nationwide registry data in Sweden 1970-2018
• Ladda ner fulltext (pdf) av Cancer survival in women diagnosed with pregnancy-associated cancer: An overview using nationwide registry data in Sweden 1970-2018

Profiling of donor-specific immune effector signatures in response to rituximab in a human whole blood loop assay using blood from CLL patients

Eltahir, mohmo394; Fletcher, E.; Dynesius, L.; Jarblad, J. L. et al.

Ingår i International Immunopharmacology, 2021

• DOI för Profiling of donor-specific immune effector signatures in response to rituximab in a human whole blood loop assay using blood from CLL patients
• Ladda ner fulltext (pdf) av Profiling of donor-specific immune effector signatures in response to rituximab in a human whole blood loop assay using blood from CLL patients

Intratumoral immunostimulatory AdCD40L gene therapy in patients with advanced solid tumors.

Irenaeus, Sandra; Hellström, Vivan; Wenthe, Jessica; Krause, Johan et al.

Ingår i Cancer Gene Therapy, s. 1188-1197, 2021

• DOI för Intratumoral immunostimulatory AdCD40L gene therapy in patients with advanced solid tumors.

TRIM study protocol - a prospective randomized multicenter Trial to assess the Role of Imaging during follow-up after radical surgery of stage IIB-C and III cutaneous malignant Melanoma

Naeser, Ylva; Helgadottir, Hildur; Brandberg, Yvonne; Hansson, Johan et al.

Ingår i BMC Cancer, 2020

• DOI för TRIM study protocol - a prospective randomized multicenter Trial to assess the Role of Imaging during follow-up after radical surgery of stage IIB-C and III cutaneous malignant Melanoma
• Ladda ner fulltext (pdf) av TRIM study protocol - a prospective randomized multicenter Trial to assess the Role of Imaging during follow-up after radical surgery of stage IIB-C and III cutaneous malignant Melanoma

Tumor endothelial ELTD1 as a predictive marker for treatment of renal cancer patients with sunitinib

Niinivirta, Marjut; Georganaki, Maria; Enblad, Gunilla; Lindskog, Cecilia et al.

Ingår i BMC Cancer, 2020

• DOI för Tumor endothelial ELTD1 as a predictive marker for treatment of renal cancer patients with sunitinib
• Ladda ner fulltext (pdf) av Tumor endothelial ELTD1 as a predictive marker for treatment of renal cancer patients with sunitinib

Complete response with combined BRAF and MEK inhibition in BRAF mutated advanced low-grade serous ovarian carcinoma.

Tholander, Bengt; Koliadi, Anthoula; Botling, Johan; Dahlstrand, Hanna et al.

Ingår i Upsala Journal of Medical Sciences, s. 325-329, 2020

• DOI för Complete response with combined BRAF and MEK inhibition in BRAF mutated advanced low-grade serous ovarian carcinoma.

European practice patterns and barriers to smoking cessation after a cancer diagnosis in the setting of curative versus palliative cancer treatment

Derksen, Jeroen W. G.; Warren, Graham W.; Jordan, Karin; Rauh, Stefan et al.

Ingår i European Journal of Cancer, s. 99-108, 2020

• DOI för European practice patterns and barriers to smoking cessation after a cancer diagnosis in the setting of curative versus palliative cancer treatment
• Ladda ner fulltext (pdf) av European practice patterns and barriers to smoking cessation after a cancer diagnosis in the setting of curative versus palliative cancer treatment

Complete and long-lasting clinical responses in immune checkpoint inhibitor-resistant, metastasized melanoma treated with adoptive T cell transfer combined with DC vaccination

Lövgren, Tanja; Wolodarski, Maria; Wickstrom, Stina; Edback, Ulrika et al.

Ingår i Oncoimmunology, 2020

• DOI för Complete and long-lasting clinical responses in immune checkpoint inhibitor-resistant, metastasized melanoma treated with adoptive T cell transfer combined with DC vaccination
• Ladda ner fulltext (pdf) av Complete and long-lasting clinical responses in immune checkpoint inhibitor-resistant, metastasized melanoma treated with adoptive T cell transfer combined with DC vaccination

Evaluation of Diffusion-Weighted MRI and FDG-PET/CT to Assess Response to AdCD40L treatment in Metastatic Melanoma Patients

Schiza, Aglaia; Irenaeus, Sandra; Ortiz-Nieto, Francisco; Loskog, Angelica S. et al.

Ingår i Scientific Reports, 2019

• DOI för Evaluation of Diffusion-Weighted MRI and FDG-PET/CT to Assess Response to AdCD40L treatment in Metastatic Melanoma Patients
• Ladda ner fulltext (pdf) av Evaluation of Diffusion-Weighted MRI and FDG-PET/CT to Assess Response to AdCD40L treatment in Metastatic Melanoma Patients

Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): protocol for a multicenter phase II open label study

Jespersen, Henrik; Bagge, Roger Olofsson; Ullenhag, Gustav; Carneiro, Ana et al.

Ingår i BMC Cancer, 2019

• DOI för Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): protocol for a multicenter phase II open label study
• Ladda ner fulltext (pdf) av Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): protocol for a multicenter phase II open label study

Tumoral pyruvate kinase L/R as a predictive marker for the treatment of renal cancer patients with sunitinib and sorafenib

Niinivirta, Marjut; Enblad, Gunilla; Lindskog, Cecilia; Pontén, Fredrik et al.

Ingår i Journal of Cancer, s. 3224-3231, 2019

• DOI för Tumoral pyruvate kinase L/R as a predictive marker for the treatment of renal cancer patients with sunitinib and sorafenib
• Ladda ner fulltext (pdf) av Tumoral pyruvate kinase L/R as a predictive marker for the treatment of renal cancer patients with sunitinib and sorafenib

First-in-human study with intratumoral administration of a CD40 agonistic antibody, ADC-1013, in advanced solid malignancies

Irenaeus, Sandra; Nielsen, Dorte; Ellmark, Peter; Yachnin, Jeffrey et al.

Ingår i International Journal of Cancer, s. 1189-1199, 2019

• DOI för First-in-human study with intratumoral administration of a CD40 agonistic antibody, ADC-1013, in advanced solid malignancies

Cancer treatment of today in view of the Nobel Prize

Ullenhag, Gustav

Ingår i Upsala Journal of Medical Sciences, s. 205-206, 2018

• DOI för Cancer treatment of today in view of the Nobel Prize
• Ladda ner fulltext (pdf) av Cancer treatment of today in view of the Nobel Prize

Adenovirus-mediated CD40L gene transfer increases Teffector/Tregulatory cell ratio and upregulates death receptors in metastatic melanoma patients

Schiza, Aglaia; Wenthe, Jessica; Mangsbo, Sara; Svensson, Emma et al.

Ingår i Journal of Translational Medicine, 2017

• DOI för Adenovirus-mediated CD40L gene transfer increases Teffector/Tregulatory cell ratio and upregulates death receptors in metastatic melanoma patients
• Ladda ner fulltext (pdf) av Adenovirus-mediated CD40L gene transfer increases Teffector/Tregulatory cell ratio and upregulates death receptors in metastatic melanoma patients

A systematic search strategy identifies cubilin as independent prognostic marker for renal cell carcinoma

Gremel, Gabriela; Djureinovic, Dijana; Niinivirta, Marjut; Laird, Alexander et al.

Ingår i BMC Cancer, 2017

• DOI för A systematic search strategy identifies cubilin as independent prognostic marker for renal cell carcinoma
• Ladda ner fulltext (pdf) av A systematic search strategy identifies cubilin as independent prognostic marker for renal cell carcinoma

Local irradiation does not enhance the effect of immunostimulatory AdCD40L gene therapy combined with low dose cyclophosphamide in melanoma patients

Irenaeus, Sandra; Schiza, Aglaia; Mangsbo, Sara M.; Wenthe, Jessica et al.

Ingår i Oncotarget, s. 78573-78587, 2017

• DOI för Local irradiation does not enhance the effect of immunostimulatory AdCD40L gene therapy combined with low dose cyclophosphamide in melanoma patients
• Ladda ner fulltext (pdf) av Local irradiation does not enhance the effect of immunostimulatory AdCD40L gene therapy combined with low dose cyclophosphamide in melanoma patients

Tumoral ANXA1 Is a Predictive Marker for Sunitinib Treatment of Renal Cancer Patients

Niinivirta, Marjut; Enblad, Gunilla; Edqvist, Per-Henrik D; Pontén, Fredrik et al.

Ingår i Journal of Cancer, s. 3975-3983, 2017

• DOI för Tumoral ANXA1 Is a Predictive Marker for Sunitinib Treatment of Renal Cancer Patients
• Ladda ner fulltext (pdf) av Tumoral ANXA1 Is a Predictive Marker for Sunitinib Treatment of Renal Cancer Patients

Shaping the Tumor Stroma and Sparking Immune Activation by CD40 and 4-1BB Signaling Induced by an Armed Oncolytic Virus.

Svensson, Emma; Milenova, Ioanna; Wenthe, Jessica; Ståhle, Magnus et al.

Ingår i Clinical Cancer Research, s. 5846-5857, 2017

• DOI för Shaping the Tumor Stroma and Sparking Immune Activation by CD40 and 4-1BB Signaling Induced by an Armed Oncolytic Virus.

Clinical and Immune Effects of Lenalidomide in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer

Ullenhag, Gustav J.; Mozaffari, Fariba; Broberg, Mats; Mellstedt, Hakan et al.

Ingår i PLOS ONE, 2017

• DOI för Clinical and Immune Effects of Lenalidomide in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer
• Ladda ner fulltext (pdf) av Clinical and Immune Effects of Lenalidomide in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer

Tumoral cubilin is a predictive marker for treatment of renal cancer patients with sunitinib and sorafenib

Niinivirta, Marjut; Enblad, Gunilla; Edqvist, Per-Henrik; Pontén, Fredrik et al.

Ingår i Journal of Cancer Research and Clinical Oncology, s. 961-970, 2017

• DOI för Tumoral cubilin is a predictive marker for treatment of renal cancer patients with sunitinib and sorafenib
• Ladda ner fulltext (pdf) av Tumoral cubilin is a predictive marker for treatment of renal cancer patients with sunitinib and sorafenib

Adenovirus-mediated CD40L gene transfer increases teffector/tregulatory cell ratio and upregulates death receptors in metastatic melanoma patients

Schiza, Aglaia; Wenthe, Jessica; Mangsbo, Sara; Eriksson, Emma et al.

Ingår i Scandinavian Journal of Immunology, s. 337-337, 2017

Activating CD40 While Inhibiting IL6R Induces Cytokine Production without PDL1 Upregulation in DCs

Eriksson, Emma; Milenova, Ioanna; Wenthe, Jessica; Moreno, Rafael et al.

Ingår i Molecular Therapy, s. 54-54, 2017

Activation of myeloid and endothelial cells by CD40L gene therapy supports T-cell expansion and migration into the tumor microenvironment

Eriksson, Emma; Moreno, R; Milenova, I. Yoanna; Liljenfeldt, L et al.

Ingår i Gene Therapy, s. 92-103, 2017

• DOI för Activation of myeloid and endothelial cells by CD40L gene therapy supports T-cell expansion and migration into the tumor microenvironment
• Ladda ner fulltext (pdf) av Activation of myeloid and endothelial cells by CD40L gene therapy supports T-cell expansion and migration into the tumor microenvironment

A case report of a patient with metastatic ocular melanoma who experienced a response to treatment with the BRAF inhibitor vemurafenib

Maleka, Aglaia; Åström, Gunnar; Bystrom, P.; Ullenhag, Gustav J.

Ingår i BMC Cancer, 2016

• DOI för A case report of a patient with metastatic ocular melanoma who experienced a response to treatment with the BRAF inhibitor vemurafenib
• Ladda ner fulltext (pdf) av A case report of a patient with metastatic ocular melanoma who experienced a response to treatment with the BRAF inhibitor vemurafenib

Gemcitabine reduces MDSCs, tregs and TGF beta-1 while restoring the teff/treg ratio in patients with pancreatic cancer

Eriksson, Emma; Wenthe, Jessica; Irenaeus, Sandra; Loskog, Angelica et al.

Ingår i Journal of Translational Medicine, 2016

• DOI för Gemcitabine reduces MDSCs, tregs and TGF beta-1 while restoring the teff/treg ratio in patients with pancreatic cancer
• Ladda ner fulltext (pdf) av Gemcitabine reduces MDSCs, tregs and TGF beta-1 while restoring the teff/treg ratio in patients with pancreatic cancer

Elevated Levels of SOX10 in Serum from Vitiligo and Melanoma Patients, Analyzed by Proximity Ligation Assay

Blokzijl, Andries; Chen, Lei; Gustafsdottir, Sigrun M.; Vuu, Jimmy et al.

Ingår i PLOS ONE, 2016

• DOI för Elevated Levels of SOX10 in Serum from Vitiligo and Melanoma Patients, Analyzed by Proximity Ligation Assay
• Ladda ner fulltext (pdf) av Elevated Levels of SOX10 in Serum from Vitiligo and Melanoma Patients, Analyzed by Proximity Ligation Assay

Immunostimulatory AdCD40L gene therapy combined with low-dose cyclophosphamide in metastatic melanoma patients

Loskog, Angelica; Maleka, Aglaia; Mangsbo, Sara; Svensson, Emma et al.

Ingår i British Journal of Cancer, s. 872-880, 2016

• DOI för Immunostimulatory AdCD40L gene therapy combined with low-dose cyclophosphamide in metastatic melanoma patients

A Phase I Dose-Escalation Study of Lenalidomide in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer

Ullenhag, Gustav J.; Rossmann, Eva; Liljefors, Maria

Ingår i PLOS ONE, 2015

• DOI för A Phase I Dose-Escalation Study of Lenalidomide in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer
• Ladda ner fulltext (pdf) av A Phase I Dose-Escalation Study of Lenalidomide in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer

The TRAIL system is over-expressed in breast cancer and FLIP a marker of good prognosis

Ullenhag, Gustav J.; Al-Attar, Ahmad; Mukherjee, Abhik; Green, Andrew R. et al.

Ingår i Journal of Cancer Research and Clinical Oncology, s. 505-514, 2015

• DOI för The TRAIL system is over-expressed in breast cancer and FLIP a marker of good prognosis

Trends in cutaneous malignant melanoma in Sweden 1997-2011: thinner tumours and improved survival among men

Lyth, J.; Eriksson, H.; Hansson, J.; Ingvar, C. et al.

Ingår i British Journal of Dermatology, s. 700-706, 2015

• DOI för Trends in cutaneous malignant melanoma in Sweden 1997-2011: thinner tumours and improved survival among men

Immunomodulatory effects of lenalidomide in combination with gemcitabine as first-line treatment in patients with advanced pancreatic cancer

Liljefors, Maria; Mozaffari, F. S.; Mellstedt, H.; Ullenhag, Gustav

Ingår i Annals of Oncology, s. 12-12, 2015

Isolated hepatic perfusion as a treatment for uveal melanoma liver metastases (the SCANDIUM trial): study protocol for a randomized controlled trial

Olofsson, Roger; Ny, Lars; All-Ericsson, Charlotta; Eilard, Malin Sternby et al.

Ingår i Trials, 2014

• DOI för Isolated hepatic perfusion as a treatment for uveal melanoma liver metastases (the SCANDIUM trial): study protocol for a randomized controlled trial
• Ladda ner fulltext (pdf) av Isolated hepatic perfusion as a treatment for uveal melanoma liver metastases (the SCANDIUM trial): study protocol for a randomized controlled trial

AdCD40L Immunostimulatory Gene Therapy in Combination with Cyclophosphamide Prolongs 6-Months Survival in a Phase I/II Trial for Malignant Melanoma

Loskog, Angelica; Maleka, Aglaia; Mangsbo, Sara; Svensson, Emma et al.

Ingår i Molecular Therapy, 2014

• DOI för AdCD40L Immunostimulatory Gene Therapy in Combination with Cyclophosphamide Prolongs 6-Months Survival in a Phase I/II Trial for Malignant Melanoma

Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study

Schadendorf, D.; Amonkar, M. M.; Milhem, M.; Grotzinger, K. et al.

Ingår i Annals of Oncology, s. 700-706, 2014

• DOI för Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study

Mortality in women with pregnancy-associated malignant melanoma

Johansson, Anna L. V.; Andersson, Therese M-L.; Plym, Anna; Ullenhag, Gustav J. et al.

Ingår i The Journal of American Academy of Dermatology, s. 1093-1101, 2014

• DOI för Mortality in women with pregnancy-associated malignant melanoma

Rapid expansion of T cells: Effects of culture and cryopreservation and importance of short-term cell recovery

Sadeghi, Arian; Ullenhag, Gustav; Wagenius, Gunnar; Tötterman, Thomas H et al.

Ingår i Acta Oncologica, s. 978-986, 2013

• DOI för Rapid expansion of T cells: Effects of culture and cryopreservation and importance of short-term cell recovery

Treatment of Metastatic Malignant Melanoma With Vemurafenib During Pregnancy

Maleka, Aglaia; Enblad, Gunilla; Sjörs, Gunnar; Lindqvist, Anna et al.

Ingår i Journal of Clinical Oncology, 2013

• DOI för Treatment of Metastatic Malignant Melanoma With Vemurafenib During Pregnancy

Whole-body MRI including diffusion-weighted imaging compared to CT for staging of malignant melanoma

Mosavi, Firas; Ullenhag, Gustav; Ahlström, Håkan

Ingår i Upsala Journal of Medical Sciences, s. 91-97, 2013

• DOI för Whole-body MRI including diffusion-weighted imaging compared to CT for staging of malignant melanoma

AdCD40L immunostimulatory gene therapy shifts the MDSC- and macrophage profiles and promotes T cell infiltration in the tumor microenvironment

Liljenfeldt, Lina; Svensson, E.; Huang, H.; Dieterich, L. et al.

Ingår i Human Gene Therapy, 2013

Treatment of metastatic malignant melanoma with vemurafenib during pregnancy

Maleka, Aglaia; Enblad, Gunilla; Sjörs, Gunnar; Lindqvist, Anna et al.

Ingår i Journal of Clinical Oncology, 2013

• DOI för Treatment of metastatic malignant melanoma with vemurafenib during pregnancy
• Ladda ner fulltext (pdf) av Treatment of metastatic malignant melanoma with vemurafenib during pregnancy

Adoptive T-cell therapy for malignant melanoma patients with TILs obtained by ultrasound-guided needle biopsy

Ullenhag, Gustav J; Sadeghi, Arian M; Carlsson, Björn; Ahlström, Håkan et al.

Ingår i Cancer Immunology and Immunotherapy, s. 725-732, 2012

• DOI för Adoptive T-cell therapy for malignant melanoma patients with TILs obtained by ultrasound-guided needle biopsy

Response to the letter to the editors from Inge Marie Svane on our manuscript "Adoptive T-cell therapy for malignant melanoma patients with TILs obtained by ultrasound-guided needle biopsy"

Wagenius, Gunnar; Ullenhag, Gustav J.; Tötterman, Thomas H.

Ingår i Cancer Immunology and Immunotherapy, s. 749-749, 2012

• DOI för Response to the letter to the editors from Inge Marie Svane on our manuscript "Adoptive T-cell therapy for malignant melanoma patients with TILs obtained by ultrasound-guided needle biopsy"

Induction of IgM, IgA and IgE Antibodies in Colorectal Cancer Patients Vaccinated with a Recombinant CEA Protein

Staff, Caroline; Magnusson, Carl G. M.; Hojjat-Farsangi, Mohammad; Mosolits, Szilvia et al.

Ingår i Journal of Clinical Immunology, s. 855-865, 2012

• DOI för Induction of IgM, IgA and IgE Antibodies in Colorectal Cancer Patients Vaccinated with a Recombinant CEA Protein

Serological and immunohistochemical analysis of S100 and derivatives as markers for prognosis of newly operated malignant melanoma patients

Bolander, Åsa; Agnarsdóttir, Margrét; Wagenius, Gunnar; Strömberg, Sara et al.

Ingår i Melanoma research, s. 412-419, 2008

• DOI för Serological and immunohistochemical analysis of S100 and derivatives as markers for prognosis of newly operated malignant melanoma patients

The Role of Circulating Angiogenic Factors in Patients Operated on for Localized Malignant Melanoma

Bolander, Åsa; Wagenius, Gunnar; Larsson, Anders; Brattström, Daniel et al.

Ingår i Anticancer Research, s. 3211-3217, 2007

Anti-EpCAM monoclonal antibody (MAb17-1A) based treatment combined with alpha-interferon, 5-fluorouracil and granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal carcinoma.

Liljefors, Maria; Ragnhammar, Peter; Nilsson, Bo; Ullenhag, Gustav et al.

Ingår i Int J Oncol, s. 703-11, 2004

Optimizing the clinical assessment of pseudoprogression in patients with solid tumors treated with checkpoint inhibitors: a systematic literature review and meta-analysis of associated features

Fountoukidis, Georgios; Tina, Elisabet; Gothlin-Eremo, Anna; Ullenhag, Gustav et al.

Ingår i Cancer Immunology and Immunotherapy, 2026

• DOI för Optimizing the clinical assessment of pseudoprogression in patients with solid tumors treated with checkpoint inhibitors: a systematic literature review and meta-analysis of associated features
• Ladda ner fulltext (pdf) av Optimizing the clinical assessment of pseudoprogression in patients with solid tumors treated with checkpoint inhibitors: a systematic literature review and meta-analysis of associated features

Discrepancy in BRAF status among patients with metastatic malignant melanoma: A meta-analysis

Valachis, Antonis; Ullenhag, Gustav

Ingår i European Journal of Cancer, s. 106-115, 2017

• DOI för Discrepancy in BRAF status among patients with metastatic malignant melanoma: A meta-analysis

AdCD40L: Crossing the Valley of Death?

Ullenhag, Gustav; Loskog, Angelica S I

Ingår i International Reviews of Immunology, s. 289-298, 2012

• DOI för AdCD40L: Crossing the Valley of Death?

Safety of intratumoral immunostimulatory LOAd703 gene therapy in patients with advanced cancer

Irenaeus, Sandra; Wenthe, Jessica; Eriksson, Emma; Schiza, Aglaia et al.

Immunological evaluation of immunostimulatory gene therapy targeting CD40/4-1BB in advanced cancer patients (LOKON002)

Wenthe, Jessica; Eriksson, Emma; Naseri, Sedigheh; Sandin, Linda et al.

Immunostimulatory gene therapy targeting CD40, 4-1BB and IL-2R activates DCs and stimulates antigen-specific T-cell and NK-cell responses in melanoma models

Wenthe, Jessica; Eriksson, Emma; Hellström, Ann-Charlotte; Moreno, Rafael et al.

LOAd703 Gene Engineering Induces Tumor Cell Immunogenicity and Enhances the Effect of Chemotherapy in Ovarian Cancer Models

Naseri, Sedigheh; Härdin, Jonas; Mejia Cordova, Mariela; Eriksson, Emma et al.